Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
by from Morbidity and Mortality Weekly Report (MMWR) on (#5V7VP)
This report describes the ACIP recommendations for two doses of RZV to prevent herpes zoster and related complications in immunocompromised adults.